Incannex Healthcare (IXHL) risk factors

64 risks, 7 new, 3 dropped, 11 reworded since the prior year. FDA layoffs and funding or staffing problems may delay Incannex’s drug reviews, approvals and inspections.

60 risks, 2 new, 7 dropped, 10 reworded since the prior year. Incannex authorized a $20 million share repurchase program while noting risks from short sellers and potential Nasdaq delisting.

65 risks. Clinical-stage biopharmaceutical company focused on cannabinoid and psychedelic drug candidates with a going concern warning. Relies heavily on Australian R&D tax incentives and requires ongoing external funding. Subject to strict controlled substance laws and potential public controversy.